Paper Details

  1. Home
  2. Paper Details

Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection.

Author: HiryakKayla, KorenDavid E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Fostemsavir (FTR) is a new treatment option for patients with multidrug-resistant HIV-1 infection. It is generally well tolerated and has few significant interactions. In phase 3 trials, FTR extended-release 600-mg tablets every 12 hours orally resulted in viral suppression in heavily treatment-experienced patients with multidrug-resistant infection refractory to other agents. Significant viral load reductions were noted within the first 24 weeks of treatment. Common adverse events include nausea, vomiting, diarrhea, fatigue, and headache. Neither renal nor hepatic dose adjustments are required.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To review the efficacy and safety of fostemsavir (FTR) for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced adults who are failing their current antiretroviral regimen. DATA SOURCES: Clinical trials and review articles were obtained through PubMed (20...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1060028020962424

データ提供：米国国立医学図書館（NLM）

Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection

Fostemsavir (FTR) is a novel antiretroviral medication that prevents HIV-1 from attaching to the host CD4 receptor. This study reviews the efficacy and safety of FTR for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced adults who are failing their current antiretroviral regimen. The authors provide a comprehensive overview of FTR's mechanism of action, clinical trial results, and adverse event profile.

FTR for Multidrug-Resistant HIV-1 Infection

The study found that FTR was effective in achieving viral suppression for patients with multidrug-resistant HIV-1 infection who were refractory to other agents. FTR was generally well-tolerated, with few significant interactions, and neither renal nor hepatic dose adjustments were required. This suggests that FTR is a promising treatment option for patients with multidrug-resistant HIV-1 infection.

Managing Multidrug-Resistant HIV-1 Infection

Managing multidrug-resistant HIV-1 infection requires a multidisciplinary approach, involving specialists in infectious diseases, virology, and pharmacy. FTR represents a valuable addition to the therapeutic arsenal for treating this challenging condition.

Dr. Camel's Conclusion

This study, like a shimmering mirage in the desert of HIV treatment, highlights the emergence of new and promising therapies. FTR offers a novel approach to tackling multidrug-resistant HIV-1 infection, providing hope for patients who have exhausted other treatment options.

Date :
  1. Date Completed 2021-08-19
  2. Date Revised 2021-08-19
Further Info :

Pubmed ID

32964736

DOI: Digital Object Identifier

10.1177/1060028020962424

Related Literature

Article Analysis
・Effects of fostemsavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.